-

Meet Selexis During Key Industry Conferences to Learn About the Latest Innovations in Cell Line Development

GENEVA--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, today announced that business and scientific leaders from the company will participate at key in-person and virtual scientific and life sciences industry partnering conferences through December 2021.

“Face-to-face meetings with the scientific community, as well as current and future customers and partners, offer significant learning and networking opportunities that help to fuel our future growth and expertise as we work to advance medicines to the clinic and, ultimately, to patients in need,” said Dirk Lange, chief executive officer at Selexis. “We are thrilled to mark our return to in-person meetings at PEGS Europe in Barcelona where much of the focus will be on those next-generation, difficult-to-express proteins – an area of cell line development in which Selexis excels and works to continually innovate.”

Following are opportunities to learn more about Selexis and its SUREtechnology Platform™ of innovative cell line development tools and modular technologies.

PEGS EUROPE Protein & Antibody Engineering Summit
2 – 4 November 2021, Hotel Arts Ritz Carlton; Barcelona, Spain (Virtual & In Person)
Selexis’ Alexandra Martiné, MSc, project leader, cell culture automation, will present “SUREtechnology Modular Approach For Expression Of Diverse Array Of Biomolecules” on Tuesday, 2 November at 4:35 p.m. CET. Additionally, Selexis is a conference sponsor and exhibitor (booth #401). For more information and to register, please visit: https://www.pegsummiteurope.com.

BIO Asia-Taiwan
4 – 7 November 2021 (In Person), Taipei Nangang Exhibition Center, Hall 2, 4F
To attend the conference or to participate in partnering discussions, please visit: https://expo.bioasiataiwan.com/en/

Festival of Biologics
9 – 11 November 2021, Congress Centre, Basel (In Person)
For more information and to register, please visit: https://www.terrapinn.com/conference/festival-of-biologics/

CPhI Worldwide
9 – 11 November 2021, Fiera Milano, Milan, Italy (In Person)
For more information and to register, please visit: https://www.cphi.com/en/home.html

BioFIT 2021
7 – 9 December 2021 (Virtual)
For more information and to register, please visit: https://www.biofit-event.com

INTERPHEX JAPAN 2021
8 December – 10 December 2021, Makuhari Messe, Japan (In Person)
For more information and to register, please visit: https://www.interphex.jp/en-gb.html

Antibody Engineering & Therapeutics
12 – 16 December 2021, Marriott Marquis San Diego (Virtual and In Person)
For more information and to register, please visit: https://informaconnect.com/antibody-engineering-therapeutics/

About Selexis SA

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 146 drug candidates in preclinical and clinical development and the manufacture of eight commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

FOR MORE INFORMATION

- Web www.selexis.com
- LinkedIn www.linkedin.com/company/selexis-sa
- Twitter www.twitter.com/SelexisSA
- Facebook www.facebook.com/SelexisSA

Contacts

Media Inquiries for Selexis
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com

Company Inquiries for Selexis
Robert Meister
Head, Corporate Communications
+1 602-953-1716
robert.meister@selexis.com

Selexis SA


Release Versions

Contacts

Media Inquiries for Selexis
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com

Company Inquiries for Selexis
Robert Meister
Head, Corporate Communications
+1 602-953-1716
robert.meister@selexis.com

More News From Selexis SA

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

GENEVA & GAITHERSBURG, Md.--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients. Per the agreement, NexImmune will leverage Selexis’ SUREtechnology Platform™...

Great Place to Work® Designates Selexis as a Best Workplace in Switzerland for Fifth Straight Year

GENEVA--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences Company, announced today that Great Place to Work® has designated the Company among the “Best Workplaces Switzerland™” in 2022. Selexis joins organizations across a broad spectrum of industries whose employees believe their workplace culture inspires trust and camaraderie. This is the fifth straight year Selexis has earned this recognition. “It is truly an honor to be granted this distinction for a fifth straight year,” said Regine Brokam...

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product

GENEVA & MOSCOW--(BUSINESS WIRE)--Selexis SA and Generium JSC today announced that Genolar®, Generium’s biosimilar of omalizumab, is now commercially available in Russia for the treatment of persistent atopic bronchial asthma and resistant chronic idiopathic urticaria. Genolar is the third Selexis SUREtechnology Platform™-generated biosimilar to reach the market under commercial license agreements between Generium and Selexis. It marks the ninth marketed biologic product to leverage Selexis’ SU...
Back to Newsroom